May 21, 2024
Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer. Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer. USA is the world's largest market for detection of pancreatic cancer. The company estimates that in the USA, 1.8 million individuals are at high-risk for pancreatic cancer and could benefit from annual surveillance testing.
» Read moreMay 3, 2024
ExpreS2ion is a biotechnology company that develops innovative vaccines for a healthier world. ExpreS2ion has developed the unique human clinical Phase III-validated technology platform, ExpreS2™, for fast and efficient development and production of the active material in vaccines. The platform, under the brand GlycoX-S2™, includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, ExpreS2ion has produced more than 500 proteins and virus-like particles (VLPs) in collaboration with leading research institutions and companies.
» Read moreApril 19, 2024
Scandion is a clinical-stage biotech company using an innovative drug efflux pump inhibition technique with biomodulation capabilities on ABCG2 and UGT1A1 targets to revert drug resistance. Drug resistance remains a massive problem in cancer treatment and in the development of new medicines. Scandion’s lead compound SCO-101 is currently studying metastatic colorectal cancer (mCRC) in its Phase 2 CORIST trial, while the PANTAX Phase 1 program is developing SCO-101 for pancreatic cancer.
» Read moreApril 5, 2024
SciBase is a global medical technology company specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to increase diagnostic accuracy and ensure the prevention of skin diseases. SciBase's commitment is to minimize patient suffering, enable physicians to improve and save lives through rapid detection and intervention, and reduce healthcare costs.
» Read moreMarch 22, 2024
The Magle Group aims to establish itself as a leader in high-quality life-changing healthcare innovations to meet medical needs through scientific excellence. The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. Today, the Group includes two operational areas. Magle Chemoswed – a contract development and manufacturing organization (CDMO) with a strong reputation for its high-quality development and manufacturing expertise and Magle PharmaCept – an established sales and marketing company for development and direct sales of the Groups medical technology products.
» Read moreMarch 18, 2024
LifeClean International offers sustainable disinfection, sanitation and cleaning solutions that address several of our biggest challenges, such as antimicrobial resistance, contamination and PFAS pollution. Among other things, LifeClean is behind the world's first climate-neutral chemical production, the world's richest detergent and a unique, patented and more environmentally friendly chemical formula based on chlorine dioxide. The chemical technology is the basis for a proven effective method for PFAS sanitation and is also verified as a spore-, fungus-, biofilm-, bacteria- and virus-killing surface disinfection. The Company operates two production facilities in Sweden, certified according to ISO 13485, ISO 14001 and ISO 9001.
» Read moreMarch 11, 2024
ChromoGenics is a proptech company that produces smart dynamic glass, improving indoor environment and well-being while reducing energy consumption, operational costs, and climate impact in real estate. The product, ConverLight® dynamic glass, is based on a unique patented technology from the Ångström Laboratory in Uppsala, where electrochromic coatings are sputtered onto plastic films. The result is a dynamic foil that can be laminated into glass, providing effective sun protection in buildings and reducing environmental impact in production, transportation, and usage. The dynamic foil is easy to transport and can be applied by local partners in the glass industry, avoiding the need for long-distance shipments of bulky glass.
» Read moreFebruary 23, 2024
Kancera is developing a new class of small molecule drugs targeting the fractalkine axis. Kancera’s main focus is to develop its candidate drugs for treatment of severe inflammatory diseases and cancer that currently lack effective treatments. The company is a leader in drug development of small molecule fractalkine blockers. Kancera is developing two drug candidates with the same mode of action; the CX3CR1 antagonists KAND567 and KAND145.
» Read moreFebruary 9, 2024
Alligator is a clinical-stage research and development-based biotechnology company that develops antibody-based drugs for cancer treatment. The Company specializes in the development of tumor-directed immunotherapies, specifically agonistic mono- and bispecific antibodies. Immunotherapy is a type of treatment that stimulates the patient’s own immune system to cure cancer. Alligator is active in the drug development phases ranging from concept and early drug discovery up to and including Phase 2 clinical studies involving patients. This includes the development and optimization of novel drug candidates, evaluation of preclinical efficacy and safety, and finally confirmatory clinical studies in cancer patients.
» Read moreJanuary 2, 2024
Fenix Family's digital B2B2C service enables customers of banks and asset managers to estate plan in a simple, fast, and safe way. This means that, based on a will, Fenix draws up a unique life plan for the end customer, their family, assets, and any loans. The plan includes legal agreements, tips on financial services and practical preparations for the family to have peace of mind here and now as well as in the future. The company's subscribers have grown strongly since launch. Growth is driven by the security Fenix creates for end consumers and partners' needs to digitalize and personalize an increasingly important aspect of financial services: estate planning.
» Read moreDecember 23, 2023
Chordate Medical is a medical technology company that has developed, patented and CE-marked Ozilia® Migraine (formerly K.O.S), a neuromodulation and drug-free treatment technology for chronic migraine and chronic rhinitis. The treatment has clinically proven efficacy according to a recent study, and is marketed in Finland, Germany, the UK, Italy, Israel, and the Gulf region.
» Read moreDecember 19, 2023
InCoax Networks re-purposes existing property coaxial networks in fiber and fixed wireless access (FWA) extension deployments for Communication Service Providers (CSP) globally. The technology is a high performance, future proof, reliable and cost-effective complement, that reduces installation time and improves take-up rate, to boost digital inclusion and Internet access for all.
» Read moreDecember 18, 2023
Svenska Aerogel manufactures and commercializes the mesoporous material Quartzene®. Svenska Aerogel's business concept is to meet the market's need for new materials that are in line with global sustainability objectives. Quartzene® is flexible and can be tailored to different applications to add essential properties to an end product. The Company's vision is to be the most valued business partner providing pioneering material solutions for a sustainable world.
» Read moreDecember 15, 2023
Saniona is an epilepsy focused clinical-stage biopharmaceutical company engaged in the discovery and development of medicines modulating ion channels. Saniona’s epilepsy pipeline includes the Phase 2 ready asset SAN711 positioned for treatment of absence seizures, the preclinical development compound SAN2219 for acute repetitive seizures and the drug-discovery program on Kv7 modulators for refractory focal onset seizures. Outside epilepsy Saniona has three clinical programs, which are positioned for partnering. The most advanced candidate, tesofensine, has progressed towards regulatory approval for obesity in Mexico by Saniona’s partner Medix, whereas Tesomet™ is ready for Phase 2b for rare eating disorders, and SAN903 is ready for Phase 1 for inflammatory bowel disease.
» Read moreDecember 13, 2023
Howwe has developed a market-leading SaaS platform that accelerates customers’ execution & financial results. The SaaS application helps CEOs and their underlying organization with digital strategy execution. The market for digital strategy execution is underdeveloped with an apparent need for an application to drive execution and digital transformation.
» Read moreDecember 6, 2023
ESTRID is a fast-growing Scandinavian razor and body care brand disrupting the European shaving market by gaining market share against established incumbents by offering fairly priced, high-quality products which are 100% vegan. ESTRID reported SEK 438 million revenue in 2022, a stunning 93% growth compared to 2021. Rapid European growth continues in 2023 with stronger profitability and the Nordics, Germany and the UK as key markets.
» Read more